CD38 antibodies inducing cell death

Feb 20, 2022

The monoclonal antibody has become instrumental for the treatment of multiple myeloma.

In this sequence, monoclonal antibodies are seen targeting CD38, a protein commonly expressed on the surface of cancerous plasma cells.

Activation of the complement system triggers the formation of pores in the cellular membrane, leading to cell death.

A goal for this sequence was to explore a visual approach that resembled a deep sea look & feel, including planktonic soft-bodied organisms and other invertebrate animals that live near the ocean floor.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , , ,


Targeting DNA methylation

Mar 04, 2021

Sequence from project that provides insight on the role aberrant DNA methylation has in the abnormalities responsible for cancer cell growth, especially hematological malignancies such as leukemia, lymphoma, and multiple myeloma.

In this sequence, we begin with a view of “normal” DNA methylation, and then change to a view of hypermethylation underway.

Eventually, decitabine – a hypomethylating agent – can be seen moving into place and blocking DNA methyltransferase (DNMT), leading to the degradation of DNMT and eventual hypomethylation.

Targeting DNA methylation with DNA hypomethylating agents (HMAs) acts to reprogram tumor cells to a more normal-like state.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , , , , , , , ,


CAR T-cell animation

A CAR T-cell therapy targeting B-cell maturation antigen (BCMA)

Apr 21, 2022

A few selected segments from a 6-minute animation created for a first-in-class B-cell maturation antigen (BCMA)-directed personalized immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.

In this CAR T therapy, the T cells are engineered to target a protein called BCMA, which is found in abundance on multiple myeloma cells, but is absent from nearly all normal cells.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , , , , ,


Immunotherapy in lung cancer

Feb 15, 2018

Activated T cells of the immune system targeting and destroying tumor cells. Once lysis occurs, the T cell moves to another cancer cell and repeats the process.

Sequence created for program that explores the impact of immunotherapies for lung cancer.

View animation >>

Tagged: , , , , , , , , , ,


Birth of a chimeric antigen receptor

Apr 02, 2020

Watch a chimeric antigen receptor (CAR) sprout from the surface of a genetically re-engineered white blood cell.

A chimeric antigen receptor (CAR) sprouts from the surface of a genetically re-engineered white blood cell.

View animation >>

Tagged: , , , , , , , , ,


The promise of antibody drug conjugates

Jul 02, 2020
What if instead of using traditional chemotherapy, antibodies could deliver a drug payload directly to tumor cells — and spare the normal cells?
In this sequence, antibody-drug conjugates can be seen here in the airway, descending down to cancerous epithelial cells and binding to specific antigens only found on targeted cells.
Monoclonal antibody technologies continue to evolve and hold great promise for the treatment of a wide number of diseases.

Tagged: , , , , , , , , , , , , , , , , , , , , , , , , , , ,


mAb targeting multiple myeloma

Feb 22, 2022

Sequence from 5-minute MOA that provides insight and details for a monoclonal antibody (mAb) designed to induce programmed tumor cell death (apoptosis) and immunomodulatory activity.

For this mechanism of action video, our task was to create a science story that would depict several key features: how the mAb finds and binds to myeloma cells and exposes them for elimination, how it boosts cells of the immune system, and how this targeted immunotherapy can kill myeloma cells directly.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , ,